{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:38:21Z","timestamp":1791805101168,"version":"4.3.4"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":39,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jtct.2025.06.013","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T07:33:19Z","timestamp":1750059199000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating the Role of CAR-T Cell Therapy in the Context of Current Therapy Options for Patients With Relapsed or Refractory Follicular Lymphoma"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2045-6238","authenticated-orcid":false,"given":"Julio C.","family":"Chavez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2166-3105","authenticated-orcid":false,"given":"Marc S.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie L.","family":"Popplewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2025.06.013_bib0001","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.jtct.2025.06.013_bib0002","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.013_bib0003","first-page":"97","article-title":"Follicular lymphoma: a focus on current and emerging therapies","volume":"36","author":"Cahill","year":"2022","journal-title":"Oncology (Williston Park)"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.013_bib0004","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016","volume":"31","author":"Press","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.06.013_bib0005","series-title":"Williams Hematology","article-title":"Follicular lymphoma","author":"Press","year":"2015"},{"issue":"12","key":"10.1016\/j.jtct.2025.06.013_bib0006","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.jtct.2025.06.013_bib0007","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.34221","article-title":"Mortality among patients with low-grade follicular lymphoma: a binational retrospective analysis","volume":"128","author":"Rajam\u00e4ki","year":"2022","journal-title":"Cancer"},{"issue":"9873","key":"10.1016\/j.jtct.2025.06.013_bib0008","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jtct.2025.06.013_bib0009","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9759","key":"10.1016\/j.jtct.2025.06.013_bib0010","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.013_bib0011","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2021.279101","article-title":"Too much and not enough: revisiting maintenance rituximab in indolent lymphomas","volume":"107","author":"Smith","year":"2022","journal-title":"Haematologica"},{"issue":"39","key":"10.1016\/j.jtct.2025.06.013_bib0012","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1200\/EDBK_239065","article-title":"One size does not fit all: who benefits from maintenance after frontline therapy for follicular lymphoma?","author":"Roschewski","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"23","key":"10.1016\/j.jtct.2025.06.013_bib0013","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.06.013_bib0014","unstructured":"Referenced with permission from NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for B-Cell Lymphomas. V.2.2025. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed April 23, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"issue":"2","key":"10.1016\/j.jtct.2025.06.013_bib0015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"S2","key":"10.1016\/j.jtct.2025.06.013_bib0016","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/hon.3196_LBA4","article-title":"TRANSCEND FL: phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed\/refractory (r\/r) follicular lymphoma (FL)","volume":"41","author":"Morschhauser","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jtct.2025.06.013_bib0017","series-title":"Package insert","year":"2024"},{"key":"10.1016\/j.jtct.2025.06.013_bib0018","series-title":"Summary of product characteristics","year":"2024"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.06.013_bib0019","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1182\/blood-2022-158024","article-title":"Long-term clinical outcomes and correlative efficacy analyses in patients (pts) with relapsed\/refractory follicular lymphoma (r\/r FL) treated with tisagenlecleucel in the ELARA trial","volume":"140","author":"Dreyling","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.06.013_bib0020","doi-asserted-by":"crossref","first-page":"10380","DOI":"10.1182\/blood-2022-156120","article-title":"3-Year follow-up analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory (r\/r) indolent non-Hodgkin lymphoma (iNHL)","volume":"140","author":"Neelapu","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.013_bib0021","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.06.013_bib0022","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood-2023-180936","article-title":"Clinical outcomes of patients with relapsed\/refractory follicular lymphoma treated with tisagenlecleucel: phase 2 ELARA 3-year follow-up","volume":"142","author":"Schuster","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.013_bib0023","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.06.013_bib0024","series-title":"Package insert","year":"2024"},{"key":"10.1016\/j.jtct.2025.06.013_bib0025","series-title":"Summary of product characteristics","year":"2024"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.06.013_bib0026","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1182\/blood-2023-174914","article-title":"Axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma: 4-year follow-up from the phase 2 ZUMA-5 trial","volume":"142","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.06.013_bib0027","series-title":"Package insert","year":"2024"},{"key":"10.1016\/j.jtct.2025.06.013_bib0028","series-title":"Summary of product characteristics","year":"2024"},{"key":"10.1016\/j.jtct.2025.06.013_bib0029","series-title":"Package insert","year":"2021"},{"issue":"9","key":"10.1016\/j.jtct.2025.06.013_bib0030","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1111\/j.1349-7006.2011.02001.x","article-title":"Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study","volume":"102","author":"Tobinai","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtct.2025.06.013_bib0031","series-title":"Package insert","year":"2024"},{"issue":"11","key":"10.1016\/j.jtct.2025.06.013_bib0032","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.013_bib0033","first-page":"394","article-title":"Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed\/refractory diffuse large B-cell lymphoma and follicular lymphoma","volume":"3","author":"Nastoupil","year":"2022","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.06.013_bib0034","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2022-162559","article-title":"Iberdomide (CC-220) monotherapy or in combination with an anti-CD20 monoclonal antibody as effective therapy in patients with relapsed\/refractory lymphoma: early results from a phase 1\/2 study","volume":"140","author":"Thieblemont","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.06.013_bib0035","series-title":"Package insert","year":"2023"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.013_bib0036","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.jtct.2025.06.013_bib0037","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.013_bib0038","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"16_suppl","key":"10.1016\/j.jtct.2025.06.013_bib0039","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.1200\/JCO.2023.41.16_suppl.7524","article-title":"High complete response rate with TNB-486 in relapsed\/refractory follicular lymphoma: interim results from an ongoing phase 1 study","volume":"41","author":"Nair","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2025.06.013_bib0040","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/bmt.2013.83","article-title":"The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT","volume":"48","author":"Robinson","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.013_bib0041","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/bmt.2015.223","article-title":"Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma","volume":"51","author":"Klyuchnikov","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2025.06.013_bib0042","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.bbmt.2015.07.028","article-title":"Reduced-intensity allografting as first transplantation approach in relapsed\/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors","volume":"21","author":"Klyuchnikov","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl","key":"10.1016\/j.jtct.2025.06.013_bib0043","first-page":"S222","article-title":"Epcoritamab with rituximab + lenalidomide (R2) provides durable responses in patients with high-risk follicular lymphoma, regardless of POD24 status","volume":"7","author":"Sureda","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.jtct.2025.06.013_bib0044","series-title":"Package insert","year":"2024"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.013_bib0045","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","article-title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial","volume":"131","author":"Bartlett","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.013_bib0046","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ajh.25659","article-title":"Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma","volume":"95","author":"Herrera","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.013_bib0047","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/1078-0432.CCR-21-2183","article-title":"Phase I\/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring","volume":"28","author":"Stewart","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"33","key":"10.1016\/j.jtct.2025.06.013_bib0048","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.013_bib0049","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/jamaoncol.2024.5412","article-title":"Second primary cancer after chimeric antigen receptor-T-cell therapy: a review","volume":"11","author":"Patel","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2025.06.013_bib0050","series-title":"Summary of product characteristics","year":"2025"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.013_bib0051","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","article-title":"Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial","volume":"17","author":"Rummel","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2025.06.013_bib0052","series-title":"Package insert","year":"2022"},{"key":"10.1016\/j.jtct.2025.06.013_bib0053","series-title":"Summary of product characteristics","year":"2024"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.013_bib0054","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.06.013_bib0055","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1182\/blood-2019-123422","article-title":"Sustained overall survival benefit of obinutuzumab plus bendamustine followed by obinutuzumab maintenance compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma: final results of the GADOLIN study","volume":"134","author":"Sehn","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.013_bib0056","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.jtct.2025.06.013_bib0057","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.jtct.2025.06.013_bib0058","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3Kdelta\/CK1epsilon inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.jtct.2025.06.013_bib0059","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.06.013_bib0060","unstructured":"U.S. Food and Drug Administration. FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns. Accessed March 25, 2024.https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approval-lymphoma-medicine-ukoniq-umbralisib-withdrawn-due-safety-concerns, 2022."},{"key":"10.1016\/j.jtct.2025.06.013_bib0061","unstructured":"Gilead Sciences Inc. Gilead statement on Zydelig\u00ae U.S. indication for follicular lymphoma and small lymphocytic leukemia. Accessed March 25, 2024.https:\/\/www.gilead.com\/company\/company-statements\/2022\/gilead-statement-on-zydelig-us-indication-for-follicular-lymphoma-and-small-lymphocytic-leukemia, 2022."},{"key":"10.1016\/j.jtct.2025.06.013_bib0062","article-title":"Secura Bio announces Copiktra\u00ae (duvelisib) strategic focus on T-cell lymphoma and voluntary U.S","year":"2021","journal-title":"withdrawal of the relapsed or refractory follicular lymphoma indication"},{"key":"10.1016\/j.jtct.2025.06.013_bib0063","unstructured":"Bayer Corporation. Bayer provides update on Aliqopa\u00ae (copanlisib). Accessed March 25, 2024.https:\/\/www.bayer.com\/en\/us\/news-stories\/update-on-aliqopar#:\u223c:text=Whippany%2C%20N.J.%2C%20November%2013%2C,FL)%20who%20have%20received%20at, 2023."},{"key":"10.1016\/j.jtct.2025.06.013_bib0064","series-title":"Summary of product characteristics","year":"2025"},{"key":"10.1016\/j.jtct.2025.06.013_bib0065","unstructured":"ClincalTrials.gov. A study of zanubrutinib plus anti-CD20 versus lenalidomide plus rituximab in participants with relapsed\/refractory follicular or marginal zone lymphoma. Accessed March 25, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT05100862, 2021."},{"issue":"4","key":"10.1016\/j.jtct.2025.06.013_bib0066","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1038\/bcj.2017.32","article-title":"EZH2 alterations in follicular lymphoma: biological and clinical correlations","volume":"7","author":"Huet","year":"2017","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.013_bib0067","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.jtct.2025.06.013_bib0068","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.jtct.2025.06.013_bib0069","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.2217\/fon-2020-1244","article-title":"Ezh2 inhibition by tazmetostat: mechanisms of action, safety and efficacy in relapsed\/refractory follicular lymphoma","volume":"17","author":"Julia","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtct.2025.06.013_bib0070","unstructured":"ClinicalTrials.gov. A study to assess the efficacy, safety, pharmacodynamics, and pharmacokinetics of tazemetostat in combination with lenalidomide plus rituximab versus placebo in combination with lenalidomide plus rituximab in adult patients at least 18 years of age with relapsed\/refractory follicular lymphoma (SYMPHONY-1). Accessed March 25, 2024. https:\/\/classic.clinicaltrials.gov\/show\/NCT04224493, 2020."},{"key":"10.1016\/j.jtct.2025.06.013_bib0071","series-title":"Summary of product characteristics","year":"2024"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.06.013_bib0072","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood-2022-158631","article-title":"Five-year results and overall survival update from the phase 3 randomized study AUGMENT: lenalidomide plus rituximab (R2) vs rituximab plus placebo in patients with relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"140","author":"Leonard","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.013_bib0073","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1182\/blood-2015-02-628669","article-title":"CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL","volume":"126","author":"Hagner","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.013_bib0074","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A Cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J Med Chem"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.06.013_bib0075","article-title":"CC-122 is more potent but transcriptionally mirrors lenalidomide in chronic lymphocytic leukemia","volume":"198","author":"Do","year":"2017","journal-title":"J Immunol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.06.013_bib0076","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood-2021-148068","article-title":"CC-99282 is a novel cereblon (CRBN) E3 ligase modulator (CELMoD) agent with enhanced tumoricidal activity in preclinical models of lymphoma","volume":"138","author":"Carrancio","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2025.06.013_bib0077","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.06.013_bib0078","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-135839","article-title":"Mosunetuzumab shows promising efficacy in patients with multiply relapsed follicular lymphoma: updated clinical experience from a phase I dose escalation trial","volume":"136","author":"Assouline","year":"2020","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.jtct.2025.06.013_bib0079","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.06.013_bib0080","series-title":"Summary of product characteristics","year":"2024"},{"key":"10.1016\/j.jtct.2025.06.013_bib0081","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory follicular lymphoma. Accessed September 2, 2024.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-follicular-lymphoma, 2024."},{"key":"10.1016\/j.jtct.2025.06.013_bib0082","series-title":"Summary of product characteristics","year":"2024"},{"key":"10.1016\/j.jtct.2025.06.013_bib0083","series-title":"Package insert","year":"2024"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.013_bib0084","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3390\/jpm11050355","article-title":"Bispecific antibodies: a review of development, clinical efficacy and toxicity in B-cell lymphomas","volume":"11","author":"Salvaris","year":"2021","journal-title":"J Pers Med"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.06.013_bib0085","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2023-174415","article-title":"Incidence of infections associated with the use of bispecific antibodies in B-cell non-Hodgkin lymphomas","volume":"142","author":"Fares","year":"2023","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.jtct.2025.06.013_bib0086","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1002\/cncr.28243","article-title":"Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project","volume":"119","author":"Evens","year":"2013","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.jtct.2025.06.013_bib0087","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/cncr.31374","article-title":"Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure","volume":"124","author":"Smith","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2025.06.013_bib0088","first-page":"328","article-title":"Referral patterns and clinical outcomes for transplant-eligible lymphoma and myeloma patients evaluated at an urban county hospital","volume":"6","author":"Yun","year":"2016","journal-title":"J Stem Cell Res Ther"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.013_bib0089","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/cancers14061501","article-title":"Cytopenia after CAR-T cell therapy-a brief review of a complex problem","volume":"14","author":"Sharma","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.013_bib0090","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1634\/theoncologist.2015-0421","article-title":"Chimeric antigen receptor T-cell therapy for the community oncologist","volume":"21","author":"Maus","year":"2016","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.013_bib0091","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jtct.2023.04.003","article-title":"Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"29","author":"Hoffmann","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.06.013_bib0092","series-title":"Relapsed and refractory follicular lymphoma","author":"Singh","year":"2024"},{"key":"10.1016\/j.jtct.2025.06.013_bib0093","series-title":"Non-Hodgkin lymphoma","author":"Sapkota","year":"2024"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.013_bib0094","first-page":"163","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceut Med"},{"issue":"35","key":"10.1016\/j.jtct.2025.06.013_bib0095","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.013_bib0096","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.013_bib0097","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.06.013_bib0098","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood-2024-205671","article-title":"Impact of prior bendamustine exposure on bispecific antibody treatment outcomes in patients with relapsed\/refractory follicular lymphoma","volume":"144","author":"Iacoboni","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.013_bib0099","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/hematology.2024000677","article-title":"Predicting bispecific antibody failure in diffuse large B-cell lymphoma","volume":"2024","author":"Barraclough","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2025.06.013_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107519","article-title":"Translational insights into the genetics and immunobiology of relapsed\/refractory follicular lymphoma","volume":"142","author":"Yaniv","year":"2024","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtct.2025.06.013_bib0101","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-01933","article-title":"Allogeneic chimeric antigen receptor T-cell products cemacabtagene ansegedleucel\/ALLO-501 in relapsed\/refractory large B-cell lymphoma: phase I experience from the ALPHA2\/ALPHA clinical studies","author":"Locke","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.013_bib0102","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/bjh.19001","article-title":"Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas","volume":"203","author":"Gao","year":"2023","journal-title":"Br J Haematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T16:28:23Z","timestamp":1754065703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725012564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":102,"alternative-id":["S2666636725012564"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.06.013","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the Role of CAR-T Cell Therapy in the Context of Current Therapy Options for Patients With Relapsed or Refractory Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}